Article

Daily Medication Pearl: Valbenazine (Ingrezza)

Valbenazine (Ingrezza) is indicated for the treatment of adults with tardive dyskinesia.

Medication Pearl of the Day: Valbenazine (Ingrezza)

Indication: Valbenazine (Ingrezza) is a vesicular monoamine transporter 2 (VMAT2) inhibitor indicated for the treatment of adults with tardive dyskinesia.

Insight:

  • Dosing:The initial dose is 40 mg once daily. After 1 week, increase the dose to the recommended dose of 80 mg once daily.
  • Dosage forms: Capsules 40 mg.
  • Adverse events: Most common adverse reaction (≥5% and twice the rate of placebo) is somnolence.
  • Mechanism of action: The mechanism of action of valbenazine in the treatment of tardive dyskinesia is unknown but is thought to be mediated through the reversible inhibition of VMAT2, a transporter that regulates monoamine uptake from the cytoplasm to the synaptic vesicle for storage and release.
  • Manufacturer: Neurocrine Biosciences

Source: INGREZZATM (valbenazine) capsules Label (fda.gov)

Newsletter

Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.

Related Videos
Inflammation concept, inflammated human tissues 3d rendering - Image credit: picture-waterfall | stock.adobe.com